Alpha-1-acid Glycoprotein as a Biomarker of Developmental Diagnosing and Monitoring Effectiveness in Sepsis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01838525

Enrollment

Registered

2013-04-24

Start date

2011-04-30

Completion date

2013-06-30

Last updated

2013-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Systemic Inflammatory Response Syndrome

Keywords

sepsis, alpha-1-acid glycoprotein (AGP), diagnosis, prognosis, SIRS

Brief summary

To assess the potential value of alpha-1-acid glycoprotein (AGP) for early diagnosis and prognosis of patients with sepsis, and then compared with C-reactive protein (CRP), procalcitonin (PCT), white blood cell (WBC) counts, Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score. 164 patients were enrolled in the study, including 25 cases with systemic inflammatory response syndrome (SIRS) and 139 cases with different levels of sepsis (46 moderate sepsis, 52 severe sepsis and 41 septic shock ). Serum levels of Alpha-1-acid Glycoprotein (AGP), C-reactive protein (CRP), and procalcitonin (PCT), and white blood cell (WBC) counts were measured on the day of admission to intensive care unit (ICU).

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Male and female aged 18 years old and over; 2. Clinically suspected infection; 3. Fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °C or lower than 36 °C (b)respiratory rate above 20/min, or PCO2 below 32 mmHg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands;

Exclusion criteria

1. less than 18 years old; 2. immunosuppression; 3. agranulocytosis (granulocyte counts \<0.5× 109/L); 4. chronic myeloid leukemia (CML); 5. malignancy; 6. less than 24 hours of the length of ICU stay; 7. reluctant to participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Patients Outcome	28 days	The survival time of patients more than 28 days is defined as survival. The survival time of patients less than 28 days is defined as death

Countries

China

Contacts

Primary ContactKun Xiao, graduate

xiaok301@163.com+86 13716608331

Outcome results